Analysis findings that demonstrated the benefit of an integrated palliative care intervention for hospitalized patients with AML were presented at the 2021 ASCO Annual Meeting.
Researchers sought to determine whether umbralisib would be an effective treatment option for patients with CLL who cannot tolerate BTK or PI3Kδ inhibitors.
Researchers sought to determine whether leukemia-specific T-cells would be a safe treatment for patients with AML or MDS after HSCT.
The tumor lysis syndrome risk decreased for 84.6% of patients in the ibrutinib/venetoclax group.
The 12-month overall survival rate was 88%.
IDH1 differentiation syndrome of any grade was noted in 14% of patients, with 1 fatal case.
The mortality rate was 0.13% in the overall chronic myeloid leukemia cohort.
Roughly a quarter of treatment cycles were administered solely as home-based treatment, with no hospital admissions required.
Researchers sought to identify a new model for predicting survival in patients with with acute myeloid leukemia.
Researchers sought to determine whether acalabrutinib may lower the rate of treatment-related AEs while maintaining a similar PFS in patients with CLL.
